Hoffmann-La Roche AG
D - 79639
39 articles with Hoffmann-La Roche AG
HERCEPTIN subcutaneous (SC) formulation approved in Canada for the treatment of HER2-positive breast cancer
SC formulation takes two to five minutes to administer, rather than up to 90 minutes with the standard intravenous (IV) formulation
Health Canada approves PERJETA (pertuzumab) for the treatment of HER2-positive early breast cancer after surgery
New treatment option can significantly reduce risk of disease recurrence or death, preventing breast cancer from returning and progressing to an incurable stage
9/4/2018Biopharm companies closed out August with a plethora of changes to executive and senior leadership positions. Let's take a look.
Gilead Sciences announced the appointment of Laura Hamill as executive vice president, Worldwide Commercial Operations, and member of the company’s senior leadership team.
HEMLIBRA is the first new treatment in almost 20 years for this most severe form of hemophilia1 and the only medicine that is self-injected once weekly
PureTech Health Announces Collaboration with Roche to Advance Technology for Oral Administration of Antisense Oligonucleotides
PureTech Health to receive up to $36 million in upfront payments, research support, and early preclinical milestones and is eligible to potentially receive over $1 billion in development milestones
GAZYVA is the first anti-CD20 treatment in 15 years for the most common subtype of indolent lymphoma.
In the deal, both companies will leverage their respective platforms, including MacroGenics’ DART platform and Roche’s CrossMAb and DutaFab technologies to select a bispecific format and lead product candidate.
Hoffmann-La Roche AG Release: Health Canada Approves TECENTRIQ (Atezolizumab) For Patients With Locally Advanced And Metastatic Bladder Cancer
ZIOPHARM, Inc. Elects George B. Abercrombie, former CEO of Hoffmann-La Roche AG, to Board of Directors
AstraZeneca AB, Merck & Co., Inc., Novartis AG, H. Lundbeck A/S, Hoffmann-La Roche AG, And GlaxoSmithKline Explore Advances in Solubility, Amorphous Forms and Lipid-Based Formulation of Drugs
Hoffmann-La Roche AG's PEGASYS(R) Study Authors Conclude that Patients Successfully Treated for Hepatitis C Can be Considered "Cured"
Roche and Synosis Therapeutics Announce Partnership To Explore Potential Of Five Compounds Targeting The Central Nervous System
Hoffmann-La Roche AG Release: Xeloda(R) Plus Avastin(R) Combination May Produce Clinical Benefit In Patients With Advanced Breast Cancer
ArQule, Inc. Initiates Phase 1 Trial With ARQ 171, Provides Enrollment Update On ARQ 501 And ARQ 197
Roche And InterMune, Inc. Sign $530M Agreement To Collaborate On The Research, Development And Commercialization Of Hepatitis C Protease Inhibitors
Four Abstracts On Roche's C.E.R.A. Accepted For Presentation At Leading European Nephrology Congress
Genentech, Inc. And Roche Holding AG Submit Supplemental Biologics License Application For Avastin(R) With Chemotherapy In First-Line, Non-Squamous, Non-Small Cell Lung Cancer